Drug Search Results

Potassium canrenoate

Alternative Names: potassium canrenoate
Latest Update: 2024-08-28
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Aldosterone Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: CHRU de Nancy
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Potassium canrenoate

Countries in Clinic: France

Active Clinical Trial Count: 1

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2019PI117	P2	Unknown Status	Unknown	2033-06-05

Recent News Events

Date	Type	Title
04/23/2024	PubMed	Establishing and Validating an Innovative Focal Adhesion-Linked Gene Signature for Enhanced Prognostic Assessment in Endometrial Cancer.
10/12/2023	PubMed	Spironolactone Eyedrop Favors Restoration of Corneal Integrity after Wound Healing in the Rat.
10/11/2023	PubMed	Potassium canrenoate in brain-dead organ donors: a randomised controlled clinical trial protocol (CANREO-PMO).

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions